LAUSANNE, Switzerland – ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma...
treatment News
LAUSANNE, Switzerland — ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). The 50-patient single-arm, open-label Phase 2 multicenter study is currently being conducted...
LAUSANNE, Switzerland – ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA™ (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines) in oncology...
New York, NY — A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer. The results were simultaneously reported in The New England Journal of Medicine and at the annual...
Houston, Texas – Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy improved progression-free survival (PFS) in patients with oligometastatic pancreatic cancer. Findings from the multicenter EXTEND trial, published today in the Journal of Clinical Oncology, were first presented at the 2024 American Society of Clinical...
Tokyo and Cambridge, Mass. — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for...
INDIANAPOLIS, Ind. — Adipo Therapeutics, a late-stage, preclinical biopharmaceutical company developing treatments for obesity and Type 2 diabetes, announced the successful completion of a $1.9 million bridge fund round. To date, Adipo has raised a total of $4 million in seed funding to advance the development of its lead asset...
VOORHEES, N.J. — Adult glioblastoma is a challenging diagnosis which carries a poor prognosis and appears to be associated with genetic alterations of several critical signaling and tumor suppressor pathways. While current treatment options are not curative, there is hope for improving outcomes for patients. In order to do this,...
LUBBOCK, Texas (KCBD) – It has been five years since medical marijuana was approved in Texas, now industry experts and patients are hoping legislators will expand qualifying conditions and change the THC cap in the upcoming session. Patients believe and experts agree: loosening rules for the Texas Compassionate Use program,...
AUSTIN, Texas – Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the publication of 20 week data from the Phase 1/2 clinical trial of pegzilarginase for the treatment of Arginase 1 Deficiency...